Amedisys (AMED) Tops Q1 EPS by 7c

Amedisys (NASDAQ: AMED) reported Q1 EPS of $1.50, $0.07 better than the analyst estimate of $1.43. Revenue for the quarter came in at $537.14 million versus the consensus estimate of $544.86 million.

Paul B. Kusserow, Chairman and Chief Executive Officer stated, “I am proud of our first quarter results and our continued performance in our four strategic pillars. Home Health has carried its strong momentum exiting 2020 into the first quarter of 2021, and though Hospice continues to see the impact of COVID-19 on average daily census, we are performing ahead of our projections and expect to continue to make good progress throughout 2021. We are also innovating close-to-the-core, growing inorganically, generating a prodigious amount of cash flow and remain in a position of very low leverage. We are excited about the growth opportunity both organically and inorganically this year and beyond and expect to be at the forefront of industry consolidation. Our industry leading quality, innovations mindset and payor orientation have materially differentiated Amedisys and have helped us take incremental steps towards being the leading aging-in-place, chronic care management company. A special thank you to all of our clinical staff and teams whose unwavering dedication to providing best-in-class clinical care has once again translated into strong financial results.”

GUIDANCE:

Amedisys sees FY2021 EPS of $6.85-$7.07, versus the consensus of $6.37. Amedisys sees FY2021 revenue of $2.302-2.342 million, versus the consensus of $2.3 million.

For earnings history and earnings-related data on Amedisys (AMED) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Carnival shares drop despite earnings beat on weak guidance
• Goldman "broadly" raises estimates for LTL and truckload stocks